Search results
Results from the WOW.Com Content Network
Peptide amphiphiles were developed in the 1990s. They were first described by the group of Matthew Tirrell in 1995. [5] [6] These first reported PA molecules were composed of two domains: one of lipophilic character and another of hydrophilic properties, which allowed self-assembly into sphere-like supramolecular structures as a result of the association of the lipophilic domains away from the ...
These assemblies have shown promise as agents of drug delivery to cancer cells. Encapsulation can control reactivity. For instance, excited state reactivity of free 1-phenyl-3-tolyl-2-proponanone (abbreviated A-CO-B) yields products A-A, B-B, and AB, which result from decarbonylation followed by random recombination of radicals A• and B•.
A notable system in this category is a nanotubular supramolecular polymer formed by the supramolecular polymerization of amphiphilic hexa-peri-hexabenzocoronene (HBC) derivatives. [26] Generally, nanotubes are categorized as 1D objects morphologically, however, their walls adopt a 2D geometry and therefore require a different design strategy ...
Ultrasound-triggered drug delivery using stimuli-responsive hydrogels refers to the process of using ultrasound energy for inducing drug release from hydrogels that are sensitive to acoustic stimuli. This method of approach is one of many stimuli-responsive drug delivery-based systems that has gained traction in recent years due to its ...
Bioprinting drug delivery is a method for producing drug delivery vehicles. It uses 3D printing of biomaterials.Such vehicles are biocompatible, tissue-specific hydrogels or implantable devices. 3D bioprinting prints cells and biological molecules to form tissues, organs, or biological materials in a scaffold-free manner that mimics living human tissue.
Ovation already owned Indocin IV, the only other drug used for this condition. Upon acquiring the only competitor for Indocin IV, Ovation raised the price of both drugs by 1,300 percent, from $36 per vial to nearly $500 per vial. [5] [6] The dramatic price increase was the subject of a 2008 Congressional hearing. [7]
Transfersome is a proprietary drug delivery technology, an artificial vesicle designed to exhibit the characteristics of a cell vesicle suitable for controlled and potentially targeted drug delivery. Some evidence has shown efficacy for its use for drug delivery without causing skin irritation, [1] potentially being used to treat skin cancer. [2]
This drug, like many others, normally requires large dosages to reach the target brain tissue diffusion from the blood, leading to systemic toxicity and the possibilities of multiple harmful side effects manifesting throughout the body. However, focused ultrasound has the potential to increase the safety and efficacy of drug delivery to the brain.